The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol

Basit Öğe Kaydı
dc.authorscopusidHüseyin Mertsoylu / 26039305600
dc.authorwosidHüseyin Mertsoylu / M-9530-2014
dc.contributor.authorTopkan, Erkan
dc.contributor.authorDurankuş, Nilüfer Kılıç
dc.contributor.authorŞenyürek, Şükran
dc.contributor.authorÖztürk, Duriye
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorMertsoylu, Hüseyin
dc.contributor.authorPehlivan, Berrin
dc.contributor.authorSelek, Uğur
dc.date.accessioned2025-05-08T10:51:15Z
dc.date.available2025-05-08T10:51:15Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, İSÜ Hastaneleri
dc.description.abstractBackground Systemic inflammation can significantly impact gliomas' onset, progression, and prognosis. Glioblastoma multiforme (GBM) represents the glioma subtype characterized by the most profound inflammatory and immunosuppressive states. Consequently, various blood-borne biomarkers have been scrutinized concerning their prognostic value in GBM patients. Objective We sought to investigate whether the recently introduced Global Immune-Nutrition-Inflammation Index (GINI) holds prognostic significance for GBM patients treated with the standard Stupp protocol. Methods We retrospectively analyzed the data from a cohort of newly diagnosed GBM patients receiving the standard Stupp regimen using the propensity score-matching methodology. The GINI was computed using the original formula: GINI = [(C-reactive protein x Monocytes x Platelets x Neutrophils) divided by (Albumin x Lymphocytes)]. We employed receiver operating characteristic (ROC) curve analysis to identify the optimal cutoff values for GINI, which could help distinguish between different survival outcomes. The primary and secondary objectives were the differences in overall survival (OS) and progression-free survival (PFS) between the GINI groups. Results The optimal GINI cutoff value was 1350. Out of 294 eligible patients, 211 were PSM-matched: GINI<1350 (N = 95) and GINI >= 1350 (N = 116). Comparative Kaplan-Meier estimates indicated that the GINI >= 1350 patients had substantially worse median PFS (8.0 vs 16.8 months; p < .001) and OS (14.3 vs 22.9 months; p < .001) durations than their GINI<1350 counterparts. Conclusion High pretreatment GINI values are robustly and independently associated with inferior PFS and OS outcomes in selected GBM patients who receive standard Stupp protocol. These findings suggest that if further confirmed, the novel GINI could serve as a valuable biological marker for the prognostic stratification of GBM patients.
dc.identifier.citationTopkan, E., Kilic Durankus, N., Senyurek, S., Öztürk, D., Besen, A. A., Mertsoylu, H., ... & Selek, U. (2024). The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol. International Journal of Immunopathology and Pharmacology, 38, 03946320241284089.
dc.identifier.doi10.1177/03946320241284089
dc.identifier.endpage13
dc.identifier.issn0394-6320
dc.identifier.issn2058-7384
dc.identifier.pmid39305006
dc.identifier.scopus2-s2.0-85204661477
dc.identifier.scopusqualityQ3
dc.identifier.startpage1
dc.identifier.urihttp://dx.doi.org/10.1177/03946320241284089
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7238
dc.identifier.volume38
dc.identifier.wosWOS:001325082900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorMertsoylu, Hüseyin
dc.institutionauthoridHüseyin Mertsoylu / 0000-0002-1932-9784
dc.language.isoen
dc.publisherSAGE publications inc.
dc.relation.ispartofInternational journal of immunopathology and pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiomarker
dc.subjectGlioblastoma Multiforme
dc.subjectGlobal Immune-Nutrition-Inflammation Index
dc.subjectPrognosis
dc.subjectSurvival
dc.titleThe global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
topkan-et-al-2024-the-global-immune-nutrition-inflammation-index-(gini)-as-a-robust-prognostic-factor-in-glioblastoma.pdf
Boyut:
798.87 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

İSÜ Hastaneleri Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu